Clinically, ipilimumab, a humanized CTLA-4 antibody and the first FDA-approved immune checkpoint inhibitor, has been demonstrated to improve OS in a phase III clinical trial for metastatic melanoma patients [76], however, with only a complete response observed in 2% patients. The gene discussed is CTLA4; the disease is metastatic melanoma.